Results 4th quarter and full year 2009
(Thomson Reuters ONE) -
Oslo, Norway, February 19, 2010
Photocure ASA (Oslo Stock Exchange: PHO) today presents its results for the
fourth quarter 2009 and for the full year 2009. A presentation will take place
today in Oslo, Norway, beginning at 11.30 am (CET) and webcast through the
Company's website www.photocure.no
The main items in the report are:
Highlights for the fourth quarter 2009
(2008 figures in brackets)
· The divestment of Metvix®/Aktilite® in September 2009 changes the
earnings profile and improves the financial position of the company.
· Photocure's strategy is to build a Specialty Pharma company.
· Hexvix® received positive feedback from FDA on 30 December, 2009.
· Revenue of NOK 14.6 million (33.2) in the fourth quarter and NOK 98.8
million in 2009 (100.9)
· Net result of NOK -19.1 million (-9.2) in the fourth quarter 2009, and
NOK 316.6 million in 2009 (-59.6)
· Paid dividend of NOK 4 per share in December, 2009
· Cash holding of NOK 403.5 million per 31 December, 2009
Key figures
+--------------------------+----------------+----------------+--------+--------+
|Figures in NOK '000 |4th quarter 2009|4th quarter 2008| 2009| 2008|
+--------------------------+----------------+----------------+--------+--------+
|Revenues | 14 556| 33 190| 98 798| 102 220|
+--------------------------+----------------+----------------+--------+--------+
|Gross profit | 12 460| 27 277| 83 329| 83 147|
+--------------------------+----------------+----------------+--------+--------+
|Research and development| - 27 289| - 25 505|- 79 492|- 78 341|
|costs | | | | |
+--------------------------+----------------+----------------+--------+--------+
|Sales and marketing costs | - 8 012| - 12 559|- 41 640|- 45 916|
+--------------------------+----------------+----------------+--------+--------+
|Operating result (EBIT) | - 29 918| - 14 469|- 59 943|- 62 539|
+--------------------------+----------------+----------------+--------+--------+
|Result | - 19 105| -9 246| 316 574|- 59 562|
+--------------------------+----------------+----------------+--------+--------+
|Earnings per share,| - 1.01| - 0.42| 14.15| - 2.70|
|diluted (NOK) | | | | |
+--------------------------+----------------+----------------+--------+--------+
Please see the full report attached.
About Photocure
Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock
Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical
devices for the photodynamic treatment and diagnosis of cancer and selected
dermatology indications.
Photocure's commercial activities includes own marketing and sales in selected
markets as well as out-licensing on a regional or global basis prior to phase
III.
Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for
the diagnosis of bladder cancer. Hexvix is approved in EU. In addition, the
company has developed a proprietary light source, which is used in combination
with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously
testing its products for new indications, and the aim is to develop a pipeline
of follow-on products based on the Photocure Technology(TM)platform.
For more information about Photocure, visit our website at www.photocure.com.
Photocure®, the Photocure logo and Hexvix® are registered trademarks of
Photocure ASA.
For further information, contact:
Attn. Kjetil Hestdal (President and CEO) or Christian Fekete (CFO)
Kjetil Hestdal mobile +47 913 19 535 - Christian Fekete mobile +47 916 42 938
E-mail: kh(at)photocure.no or cf(at)photocure.no
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1386385]
Results: http://hugin.info/131151/R/1386385/345038.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.02.2010 - 02:29 Uhr
Sprache: Deutsch
News-ID 1010619
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Oslo
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 252 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Results 4th quarter and full year 2009
"
steht unter der journalistisch-redaktionellen Verantwortung von
Photocure ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
